Clarity provides Australia’s first commercial PET imaging service to biopharmaceutical companies
Clarity Pharmaceuticals has technology that allows biologic drugs to be seen inside the body, providing Australia’s first commercial PET imaging service to biopharmaceutical companies. By utilising its proprietary technology, Clarity Pharmaceuticals helps to visualise biologics as they work in the body and determine their efficiency using the highest resolution modality –PET. The generated data enables biopharmaceutical companies to make educated decisions regarding their drug candidates and de-risk the development process.
Clarity utilises a novel range of chemical compounds called ‘chelators’, which are bound to biologics and enable them to be seen in the body through molecular PET imaging. This allows gaining powerful data on the drug’s distribution and targeting in vivo, further leading to significant cost savings for developers by providing early feedback. Clarity’s chelators are better suited to PET imaging of biologics as they are able to bind the isotope of copper, copper-64. Copper-64 enables more precise biopharmaceutical imaging due to its half-life of 13 hours, thus producing images at the optimal time point for biologics where the other commercially available chelators and isotopes cannot.
Clarity’s molecular imaging is an essential tool in the personalised medicine field as it can be used for diagnosis, spread of disease and personalised dosing estimates, monitoring treatment response and determining if a patient is disease-free after treatment. The ability to monitor the effectiveness of a therapy is called theranostics and the tool is a companion diagnostic. Clarity is focussed on designing and developing companion diagnostics by sourcing promising biopharmaceuticals that are known to localise at a disease site. Using Clarity’s chelator technology we can add a tracer to these biopharmaceuticals allowing the disease site to be imaged using PET.
Clarity’s technology also has the ability to generate targeted therapeutics by delivering high-energy isotopes or large radioactive doses to target sites to provide localised radiotherapy.
What are radiopharmaceuticals?
Radiopharmaceuticals combine the targeting and binding properties of pharmaceuticals and the emissions from radioactive isotopes, to either diagnose or treat disease. Today radiopharmaceuticals are mostly used to provide diagnostic information about cancer and to treat some life-threatening diseases.
The Radiopharmaceutical/Nuclear medicine global market is expected to grow at a CAGR of more than 5.5% to reach $9 billion by 2020 (PRWeb 2014). Such a rapid development is driven by the increasing popularity of PET scans, growing incidences of cancer and cardiac ailments, and rising awareness and availability of radiopharmaceuticals. Novel technology and new uses of existing technologies, such as hybrid imaging, will further fuel market dynamics.
This article originally appeared on Clarity. Keep your eyes posted for more information shortly.